The presence of an early repolarization pattern (ERP) on the surface electrocardiogram (ECG) is 88 associated with risk of ventricular fibrillation and sudden cardiac death. Family studies have shown 89 that ERP is a highly heritable trait but molecular genetic determinants are unknown. We assessed the 90 ERP in 12-lead ECGs of 39,456 individuals and conducted a two-stage meta-analysis of genome-wide 91 association studies (GWAS). In the discovery phase, we included 2,181 cases and 23,641 controls 92 from eight European ancestry studies and identified 19 genome-wide significant (p<5E-8) variants in 93 the KCND3 (potassium voltage gated channel subfamily D member 3) gene with a p-value of 4.6E-10. 94
Introduction 107
The early repolarization pattern (ERP) is a common ECG finding characterized by an elevation at the 108 QRS-ST junction (J-point) of at least 0.1 mV in two adjacent ECG leads. The prevalence of ERP in the 109 general population ranges from 2 to 13% being more common in young athletic men (1) (2) (3) (4) (5) . The 110 classical notion of ERP being a benign ECG phenotype was challenged in 2008 by the landmark study 111 of Haissaguerre and colleagues showing an association of ERP with increased risk of ventricular 112 fibrillation and sudden cardiac death(6): the Early Repolarization Syndrome (ERS)(7). Since then 113 several studies demonstrated an elevated risk of cardiovascular and all-cause mortality in individuals 114 with ERP underscoring its arrhythmogenic potential (2, 8, 9) . Although the mechanistic basis for 115 malignant arrhythmias in ERS is unclear, it has been suggested that they occur as a result of an 116 augmented transmural electrical dispersion of repolarization. Ex vivo studies point towards a central 117 role of the cardiac transient outward potassium current (I to ) in the development of both, ERP and 118 ERS(10). Furthermore, case descriptions of ERS identified genetic variations in genes encoding 119 proteins for cardiac ion channels (11) (12) (13) . Studies among relatives of sudden arrhythmic death 120 syndrome show that ERP is more prevalent in the relatives than in controls indicating that ERP is an 121 important potentially inheritable pro-arrhythmic trait (14, 15) . Moreover, in family studies the heritability 122 estimate for the presence of ERP was h 2 =0.49 (16). However, estimates for common SNP heritability 123 from unrelated individuals are lower(17). This may explain why the only available genome-wide 124 association study (GWAS) on ERP failed to identify genetic variants reaching genome-wide 125 significance(18), and indicates the need for GWAS with more power by including a larger number of 126 ERP cases. 127
Novel variants associated with ERP 136
We performed a GWAS meta-analysis in up to 2,181 cases and 23,641 controls from eight discovery 137 cohorts. In total, 6,976,246 SNPs passed quality control (see Methods). We identified 19 variants 138 spanning 49 kb in KCND3 (Potassium Voltage-Gated Channel Subfamily D Member 3) as well as 139 rs139772527 (effect allele frequency [EAF] 1.4%, OR=2.57, p=2.0E-8) near HBZ (Hemoglobin Subunit 140 Zeta) to be genome-wide significantly associated (p<5E-8) with ERP The SNP with the lowest p-value 141 of the region (lead SNP) at KCND3 was the intronic rs12090194 (EAF 32.5%, OR=0.80, p=4.6E-10), 142
and was replicated in an independent sample of 1,124 cases and 12,510 controls from four additional 143 cohorts (p replication =2.5E-3, p combined =9.3E-12, Table 2 ). The SNP rs139772527 near HBZ did not fulfil 144 the criteria for replication (p replication =0.28, p combined =1.4E-6, Table 2) as described in the Methods. The 145 combined meta-analysis of all 12 cohorts including up to 39,456 individuals revealed only the locus at 146 KCND3 to be genome-wide significantly associated with ERP (Supplementary Figure 1) . The lead 147 SNP was rs1545300 (EAF 31.9%, OR=0.82, p=7.7E-12), followed by the discovery stage lead SNP 148 rs12090194 being in strong linkage disequilibrium with rs1545300 (r²=0.96, D'=1) (Figure 1) Figure 2) . Summary statistics based conditional analysis to select 153 independent hits did not reveal any secondary signals. 154
Statistical finemapping of the associated locus 155
All significantly associated SNPs were located within KCND3, the potassium voltage-gated channel 156 subfamily D member 3 gene and were intronic. We used the discovery and replication stage combined 157 GWAS results to assess whether a single SNP or set of variants drive the association signal in 158 KCND3 (credible set). The 99% credible set was computed based on Approximate Bayes Factors for 159 each SNP, resulting for each in a set of SNPs that with 99% posterior probability contained the 160 variant(s) driving the association signal. For the associated locus at KCND3 the credible set spanned 161 49 kb, and contained 19 variants. The two lead SNPs rs1545300 and rs12090194 had a posterior 162 probability of 21% and 19%, respectively, whereas the former candidate SNP rs17029069(18) had a 163 posterior probability of 2% ( Supplementary Table 2 ). 164
To test whether the association in KCND3 might be driven by heart rate or RR interval, we performed 165 a sensitivity analysis in the 1,253 ERP cases and 11,463 controls of the Lifelines cohort adjusting the 166 genetic association of rs1545300 additionally for these two traits in separate models. The effect 167 estimates were virtually unchanged (OR=0.78) with p=1.2E-7 for both adjustments. In addition, we 168 assessed whether the association of rs1545300 might be related to a specific ERP subtype i.e ST 169 segment or ERP localization. In all subtype-stratified analyses the 95% confidence intervals of the 170 effect sizes overlapped with the overall results not pointing to a subtype driven signal (Supplementary 171 We searched the Genotype-Tissue Expression (GTEx) project database(20) to look for tissue-specific 174 eQTLs including all genes in vicinity of ±1Mb of the lead SNP rs1545300 and found an association 175 with KCND3 expression levels in tibial artery (p=3.0E-6, n=388). Two additional eQTL associations of 176 rs1545300 at a false discovery rate (FDR) <0.2 across the 48 tissues tested were found with KCND3 177 (ENSG00000171385.5) in the left ventricle (p=2.9E-4, n=272) of the human heart, and with CEPT1 178 (ENSG00000134255.9) in the minor salivary gland (p=3.4E-4, n=97) ( Supplementary Table 4 ). 179 Subsequent co-localization analyses of rs1545300 in these three tissues revealed also a significant 180 correlation of gene expression pattern with ERP (p SMR ≤ 0.01) (Figure 2 , Supplementary Table 5 ), 181
where for the left ventricle the correlation seems to be attributable to the same underlying causative 182 variant (p HEIDI ≥ 0.05), and for tibial artery the test was close to nominal significance (p HEIDI =0.05). 183 However, the significant p HEIDI =1.7E-3 of CEPT1 in the minor salivary gland points rather towards a 184 pleiotropic effect of rs1545300 than to a causal effect of gene expression on ERP in this tissue. For all 185 three tissues, an increased gene expression level was associated with a higher risk of ERP 186 ( Supplementary Table 5 ). 187
Pleiotropic effects of the lead SNPs 188
To assess pleiotropic effects of the KCND3 lead SNP rs1545300 or its proxies (r²>0.8), we looked for 189 genome-wide significant associations in the NHGRI-EBI Catalog of published genome-wide 190 association studies(21) (accessed: 05/03/2019). Pleiotropic associations were found for P-wave 191 terminal force (rs12090194 and rs4839185)(22) and for atrial fibrillation (rs1545300 and 192 rs1443926)(23, 24). All these SNPs were in strong linkage disequilibrium (r²>0.97) with the lead SNP. 193 In addition, variants in low to moderate LD with rs1545300 were associated with P-wave duration 194 (rs2798334, r²=0.26)(25) and ST-T-wave amplitudes (rs12145374, r²=0.60)(26). 195
Discussion 196
In this GWAS meta-analysis comprising 3,305 cases and 36,151 controls including independent 197 replication samples, we describe an association of ERP with a locus on chromosome 1 in the KCND3 198 gene. This is the first study identifying a robust genome-wide significant association between genetic 199 variants and ERP. Our findings form the genetic basis for further functional studies examining the 200 pathophysiological mechanism of ERP and potentially ERS. The KCND3 gene encodes the main 201 pore-forming alpha subunit of the voltage-gated rapidly inactivating A-type potassium channel. In the 202 cardiac ventricle KCND3 contributes to the fast cardiac transient outward potassium current (I to ), which 203 plays a major role in the early repolarization phase 1 of the cardiac action potential (AP). 204
To date, two competing theories explain the presence of J waves and ERP: the repolarization and the 205 depolarization theory, both involving the I to channel. On the basis of animal models evidence for the 206 former is more compelling. Thus, J waves result from a transmural voltage gradient created by a more 207 prominent epicardial phase 1 AP notch relative to the endocardial AP notch(10, 27). The I to current 208 notably influences the degree of the transmural heterogeneity of the phase 1 AP notch and 209 consecutively the magnitude of the J wave(10, 27). Pharmacological inhibition of the I to current with 4-210 aminopyridine results in a reduction of the J wave amplitude(10). The depolarization theory is based 211 on clinical overlap of ERP with Brugada syndrome, which has led to the suggestion of Brugada 212 syndrome being a right ventricular variant of the ERP(28). In theory, deviation from the sequential 213 activation of cardiac currents I Na , I to , and I CaL can lead to regional conduction slowing and appearance 214 of inferior and/or lateral ERP(27, 29). In patients with ERS, distinct phenotypes of both delayed 215 depolarization and early repolarization have been identified(30). 216 ERP is a highly heritable trait within families(3, 16), however limited heritability can be attributed to 217 common SNPs in unrelated individuals(17). This might be a reason why the only GWAS to date which 218 included 452 cases failed to replicate any genome-wide significant loci(18). In our study, which 219 includes 3,334 cases, we discovered and replicated variants in the KCND3 gene. Interestingly, one of 220 these variants (rs17029069), which is in moderate LD (r²=0.18, D'=-1) with our lead SNP rs1545300 221 ( Supplementary Figure 3) was reported as a candidate in the earlier GWAS meta-analysis(18). 222
However, this variant did not replicate in their study, which the authors attributed to limited power 223 based on the small sample size and/or heterogeneous phenotyping. In our study, experienced 224 cardiologists centrally adjudicated more than 39,000 ECGs with high reproducibility ensuring a very 225 high phenotyping quality(17). The resulting homogenously assessed phenotype and the substantially 226 increased number of cases are two aspects that elevated the statistical power of our GWAS meta-227 analysis. All detected variants cluster in intronic regions of the KCND3 gene, without significant allelic 228 heterogeneity. The annotation of the locus does not point to a direct pathogenic effect, i.e. a protein 229 altering mutation, and also the statistical finemapping revealed no single SNP with a substantial 230 posterior probability (e.g. >80%) of being causal. However, the latter approach has limitations of 231 detecting rare causal variants due to imputation uncertainty and minimum minor allele frequency 232 (MAF). Nevertheless, eQTL analysis suggested that the detected variants may affect gene expression 233 of KCND3. Potential mechanisms include modification of gene expression via altered binding of 234 transcription factors at cis-elements. This is supported by the results of the test for co-localization 235
showing an increase of ERP risk due to increased gene expression levels of KCND3 in tissues of the 236 human heart and tibial artery. Similar, pharmacological ex vivo data predict gain of function mutations 237
in the I to current to increase the overall transmural outward shift, leading to an increased epicardial AP 238 notch and thereby inducing ERP in the surface ECG(27). Additionally, in close proximity to the lead 239 SNP rs1545300 a long non-coding RNA (lncRNA), KCND3 antisense RNA 1 (KCND3-AS1) is 240 described. LncRNAs have been shown to physiologically influence gene regulation through various 241 mechanism e.g. chromatin remodeling, control of transcription initiation and post-transcriptional 242 processing(31, 32). On the other hand, dysregulation of lncRNA control circuits can potentially impact 243 development of disease(33): a very prominent example in cardiovascular diseases is the lncRNA 244 ANRIL, which is a key effector of 9p21 in atherosclerotic risk and cardiovascular events(33-35). 245
Given the high prevalence of ERP in the general population and a high MAF of the identified genetic 246 variants in our study the key question remains why only a very small subset of individuals develops 247 severe ventricular arrhythmias and ERS. The fine interplay of a genetic predisposition and specific 248 precipitating conditions might lead to an electrically vulnerable cardiac state. Insights into the potential 249 origin of ventricular arrhythmias in ERS come from animal models and highlight the role of different ion 250 channels including I to (36). A pharmacological model of ERS in canine wedges from the inferior and 251 lateral ventricular wall showed marked regional dispersion of repolarization (loss of phase 2 AP dome 252 and AP shortening in some epicardial regions but not others). Presence of transmural repolarization 253 heterogeneity allowed local re-excitation in form of closely coupled extrasystolic activity (phase 2 re-254 entry). The combination of an arrhythmogenic substrate, represented by regional electrical instability, 255 and triggering premature ventricular beats resulted in ventricular fibrillation(36). Human data in ERS 256 patients suggest that in a subgroup, the ERP is due to a pure repolarization phenotype and 257 arrhythmia(30) is triggered by Purkinje fiber ectopic beats. 258
Genetic variants in various ion channel genes have been associated with ERS(37) including the 259 Our study has some limitations, which need to be acknowledged. Presence of ERP in the ECG can be 278 variable, as it has been described to be dependent on age, heart rate, vagal activity and medication, 279 although our findings were valid after adjusting for some of these factors. Therefore, we cannot 280 exclude that we have missed some individuals with ERP. Second, the tissue-specific gene expression 281 data used for the co-localization analysis is based on a limited sample size. A larger gene expression 282 sample or functional studies are needed to validate the revealed effect of KCND3 expression on the 283
ERP. 284
In conclusion, we show for the first time, a robust association of genetic variants with the ERP in a 285 large GWAS of individuals of European ancestry. The locus in the KCND3 ion channel gene is an 286 intuitive candidate and supports the theory that at least a proportion of ERS is a pure channelopathy. 287
Intensive future research will be needed to extend the discovery of ERP susceptibility loci to 288 individuals of non-European ancestry, and to improve identification and risk stratification of the subset 289 of individuals with the ERP who are at highest risk for potentially lethal ventricular arrhythmias. 290
Methods 291

Study cohorts and SNP genotyping 292
The discovery stage included 25,822 subjects (2,181 ERP cases) from eight independent cohorts: the 293 Table 1 ). All subjects gave written informed consent and the 301 studies were approved by the local ethics committees. 302
Electrocardiogram analysis and ERP evaluation 303
12-lead ECGs of all 12 studies were analyzed manually by experienced and specifically trained 304 cardiologists for the presence of ERP according to the established definition by Haissaguerre and 305 Macfarlane(6, 19). In case of a QRS duration of >120 ms or rhythm other than sinus rhythm (e.g. atrial 306 fibrillation, pacemaker stimulation) ECGs were excluded from the analysis. The methodology 307 employed and robustness of inter-observer correlations have been presented elsewhere(17). 308
In detail, ERP was defined as elevation of the J-point above the level of QRS onset of ≥ 0.1 mV in at 309 least two corresponding leads. To avoid confusion or overlap with Brugada syndrome or 310 arrhythmogenic right ventricular dysplasia, leads V1 to V3 were excluded from ERP scoring. In case of 311 presence of ERP, region, either inferior (leads II, III, aVF), antero-lateral (leads I, aVL, V 4 -V 6 ), or both, 312 and the maximum amplitude of J-point elevation was documented. Further, the morphology of ERP 313 was assessed as either notching, slurring or both as well as the ST segment according to Tikkanen 314 and collegues(41) as either concave/rapidly ascending (>0.1 mV elevation 100 ms after J-point peak 315 or persistently elevated ST segment >0.1 mV) or horizontal/descending (≤0.1 mV elevation within 100 316 ms after J-point peak)(19, 41). 317
GWAS in individual studies 318
The GWAS in each study for both the discovery and replication stage was performed on autosomal 319 imputed SNP genotypes using study-specific quality control protocols which are provided in detail in 320 Supplementary Table 1 . Association analyses were performed using logistic regression for ERP 321 status as outcome and an additive genetic model on SNP dosages, thus taking genotype uncertainties 322 of imputed SNPs into account. The analyses were adjusted for age, sex, and relevant study-specific 323 covariates such as principal components for population stratification (Supplementary Table 1) . 324
Statistical methods for meta-analysis 325
The result files from individual studies GWAS underwent extensive quality control before meta-326 analysis using the gwasqc() function of the GWAtoolbox package v2.2.4(42). The quality control 327 included file format checks as well as plausibility and distributions of association results including 328 effect sizes, standard errors, allele frequencies and imputation quality of the SNPs. 329
The meta-analyses were conducted using a fixed-effect inverse variance weighting as implemented in 330 Metal(43). Monomorphic SNPs, SNPs with implausible association results (i.e. p≤0, SE≤0, 331 |log(OR)|≥1000), and SNPs with an imputation quality score ≤ 0.4 were excluded prior to the meta-332 analyses resulting in a median of 12,839,202 SNPs per cohort (IQR: 10,756,073-13,184,807). During 333 the meta-analysis, the study-specific results were corrected by their specific λ GC if >1. Results were 334 checked for possible errors like use of incorrect association model by plotting the association p-values 335 of the analyses against those from a z-score based meta-analysis for verifying overall concordance. 336
SNPs that were present in <75% of the total sample size contributing to the respective meta-analysis 337 or with a MAF ≤ 0.01 were excluded from subsequent analyses. Finally, data for up to 6,976,246 SNPs 338 were available after the meta-analysis. 339
Quantile-quantile plots of the meta-analysis results are provided in Supplementary Figure 2 . To 340 assess whether there was an inflation of p-values in the meta-analysis results attributed to reasons 341 other than polygenicity, we performed LD score regression(44). The LD score corrected λ GC value of 342 the discovery and replication combined meta-analysis was 1.01, supporting the absence of 343 unaccounted population stratification. Genome-wide significance was defined as a p-value <5E-8, 344 corresponding to a Bonferroni correction of one million independent tests. Unless stated otherwise, all 345 reported p-values are two-sided. The I 2 statistic was used to evaluate between-study 346 heterogeneity(45). 347
To evaluate the presence of allelic heterogeneity within each locus, the GCTA stepwise model 348 selection procedure (cojo-slct algorithm) was used to identify independent variants employing a step-349 wise forward selection approach(46). We used the genotype information of 4,081 SHIP individuals for 350 LD estimation, and set the significance threshold for independent SNPs to 5E-8. 351
All loci were named according to the nearest gene of the lead SNP. Genomic positions correspond to 352 build 37 (GRCh37). 353
Replication analysis 354
To minimize the burden for multiple testing correction and thus maximizing the power for replication, 355 the lead SNPs of genome-wide significant loci in the discovery stage were taken forward to the 356 replication stage in independent samples ( Table 1) . SNPs were considered as replicated if the p-value 357 of a one-sided association test was <0.025 which corresponds to a Bonferroni correction for the two 358 lead SNPs tested at 5% significance level. 359
Finally, the GWAS results from the discovery and replication studies were meta-analyzed to search for 360 additional genome-wide significant loci by maximizing the statistical power for locus discovery. 361
Gene expression based analyses 362
The lead SNP rs1545300 of the KCND3 locus of the combined discovery and replication GWAS meta-363 analysis was tested for cis eQTLs (±1Mb window around the transcription start site) in 48 tissues 364 available in the GTEx v7 database that included at least 70 samples. Significant associations were 365 selected based on a Bonferroni corrected p-value <3.0E-5 for the number of genes and tissues tested. 366
Subsequently, the SNP rs1545300 was tested and plotted for co-localization in the three tissues with 367 an eQTL FDR<0.2 by applying the SMR method(47) using the GWAS and GTEx eQTL summary A1: effect allele; AF1: allele frequency of A1; OR: odds ratio of A1 [95% confidence interval]; P: association p-value; I²: percentage of total variation across studies that is due to heterogeneity; N: sample size. Bold values indicate the lead SNP (lowest p-value) of a significantly associated locus in the corresponding meta-analysis stage.
